{"id":728400,"date":"2023-02-02T16:23:47","date_gmt":"2023-02-02T21:23:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"modified":"2023-02-02T16:23:47","modified_gmt":"2023-02-02T21:23:47","slug":"viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","title":{"rendered":"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"},"content":{"rendered":"
\n

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the \u201cCompany\u201d or \u201cViridian\u201d), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 332,000 shares of the Company\u2019s common stock to four new employees (the \u201cInducement Grants\u201d) on February 1, 2023 (the \u201cGrant Date\u201d). The Inducement Grants have been granted outside of the Company\u2019s Amended and Restated 2016 Equity Incentive Plan (the \u201cPlan\u201d) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian\u2019s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee\u2019s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee\u2019s continued employment with Viridian through the applicable vesting dates.<\/p>\n

\n About Viridian Therapeutics<\/strong>\n <\/p>\n

Viridian Therapeutics\u00a0is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian\u2019s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.<\/p>\n

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called \u2018THRIVE\u2019 to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.<\/p>\n

Viridian is based in\u00a0Waltham,\u00a0Massachusetts. For more information, please visit\u00a0www.viridiantherapeutics.com<\/u><\/a>. Follow Viridian on\u00a0LinkedIn<\/u><\/a>.<\/p>\n

\n Investor and Media Contact:<\/strong><\/p>\n

Viridian Therapeutics, Inc.<\/p>\n

Louisa Stone, 508-808-2400
Manager, Investor Relations
IR@viridiantherapeutics.com<\/a><\/p>\n

Todd James, 617-272-4691
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com<\/a><\/p>\n

Source:\u00a0Viridian Therapeutics, Inc.<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the \u201cCompany\u201d or \u201cViridian\u201d), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 332,000 shares of the Company\u2019s common stock to four new employees (the \u201cInducement Grants\u201d) on February 1, 2023 (the \u201cGrant Date\u201d). The Inducement Grants have been granted outside of the Company\u2019s Amended and Restated 2016 Equity Incentive Plan (the \u201cPlan\u201d) but remain subject to the terms and conditions of such Plan. The Inducement Grants were … <\/p>\n

Continue reading “Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728400","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the \u201cCompany\u201d or \u201cViridian\u201d), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 332,000 shares of the Company\u2019s common stock to four new employees (the \u201cInducement Grants\u201d) on February 1, 2023 (the \u201cGrant Date\u201d). The Inducement Grants have been granted outside of the Company\u2019s Amended and Restated 2016 Equity Incentive Plan (the \u201cPlan\u201d) but remain subject to the terms and conditions of such Plan. The Inducement Grants were … Continue reading "Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-02T21:23:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\",\"datePublished\":\"2023-02-02T21:23:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"wordCount\":425,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"name\":\"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==\",\"datePublished\":\"2023-02-02T21:23:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_locale":"en_US","og_type":"article","og_title":"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","og_description":"WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the \u201cCompany\u201d or \u201cViridian\u201d), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company\u2019s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 332,000 shares of the Company\u2019s common stock to four new employees (the \u201cInducement Grants\u201d) on February 1, 2023 (the \u201cGrant Date\u201d). The Inducement Grants have been granted outside of the Company\u2019s Amended and Restated 2016 Equity Incentive Plan (the \u201cPlan\u201d) but remain subject to the terms and conditions of such Plan. The Inducement Grants were … Continue reading \"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-02T21:23:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","datePublished":"2023-02-02T21:23:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"wordCount":425,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","name":"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==","datePublished":"2023-02-02T21:23:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjAzMiM1Mzg5NjMzIzUwMDEwNDAzNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728400"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}